Tallink Grupp
Dividend payment ex-date of AS Tallink Grupp
Dividend payment ex-date of AS Tallink Grupp
The General Meeting of Shareholders held on 20 May 2025 decided to pay the shareholders dividends of EUR 0.06 per share. The first instalment of EUR 0.03 per share was paid out on 2 July 2025. The second instalment of EUR 0.03 per share will be paid out on 25 November 2025.
The list of AS Tallink Grupp’s shareholders entitled to the dividend shall be fixed as at 14 November 2025 at the end of the business day of the settlement system of the securities registrar (record-date).
Consequently, the day of change of the rights related to the shares (ex-date) is 13 November 2025. From this day onwards, the persons acquiring the shares (TAL1T, ISIN: EE3100004466) or Finnish Depository Receipts („FDR“s; ISIN FI4000349378) are not entitled to the right to receive dividends.
The dividend shall be paid to the shareholders by transfer to the bank account of the shareholders on 25 November 2025.
Anneli Simm
Investor Relations Manager
AS Tallink Grupp
Sadama 5
10111 Tallinn
E-mail Anneli.simm@tallink.ee
Phone: +372 56157170
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S7.12.2025 13:50:00 CET | Press release
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
SALI7.12.2025 02:14:21 CET | Press release
SALI Showcases Global Ambition with Times Square Billboard Campaign, Marking a New Milestone in Its Journey Toward a Global Power Tool Accessories Empire
Evaxion6.12.2025 20:00:00 CET | Press release
Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting
Genmab A/S6.12.2025 15:30:00 CET | Press release
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
Io Therapeutics, Inc.6.12.2025 14:05:00 CET | Press release
Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom